Public Release: 

Stronger nicotine dependence correlates with higher post-smoking weight gain

Post smoking weight gain correlates with nicotine dependence, serum lipid levels

PLOS

Smokers with more severe nicotine dependence are more likely to gain weight when they try to quit, according to research published August 21 in the open access journal PLOS ONE by Koji Hasegawa and colleagues from Kyoto Medical Center, Japan.

Even with nicotine replacement therapy, individuals can gain substantial amounts of weight when they quit smoking. Here, researchers studied weight gain patterns in individuals who successfully abstained from smoking after nicotine replacement therapy at a clinic. They found that higher scores on the Fagerström Test for Nicotine Dependence (FTND), implying more severe dependence, correlated strongly with the amount of weight participants gained when they quit. Other factors that were significantly associated with post-smoking weight gain were higher serum triglycerides and lower HDL-cholesterol levels at the start of therapy and the number of cigarettes participants reported smoking each day. There was no significant difference in weight gain between patients who used nicotine patches and those that used the oral pill varenicline. Based on their results, the authors suggest that smokers with higher nicotine dependency may require interventions against weight gain in the cessation clinic.

###

Citation: Komiyama M, Wada H, Ura S, Yamakage H, Satoh-Asahara N, et al. (2013) Analysis of Factors That Determine Weight Gain during Smoking Cessation Therapy. PLoS ONE 8(8): e72010. doi:10.1371/journal.pone.0072010

Financial Disclosure: This work was supported in part by a Grant-in-Aid for Clinical Research from the National Hospital Organization and the Pfizer Health Research Foundation (to KH). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interest Statement: One drug studied in the work, varenicline, is manufactured by Pfizer. While funding was received from Pfizer Health Research Foundation, the authors confirm that this does not alter their adherence to all the PLOS ONE policies on sharing data and materials.

PLEASE LINK TO THE SCIENTIFIC ARTICLE IN ONLINE VERSIONS OF YOUR REPORT (URL goes live after the embargo ends): http://dx.plos.org/10.1371/journal.pone.0072010

Disclaimer: This press release refers to upcoming articles in PLOS ONE. The releases have been provided by the article authors and/or journal staff. Any opinions expressed in these are the personal views of the contributors, and do not necessarily represent the views or policies of PLOS. PLOS expressly disclaims any and all warranties and liability in connection with the information found in the release and article and your use of such information.

About PLOS ONE: PLOS ONE is the first journal of primary research from all areas of science to employ a combination of peer review and post-publication rating and commenting, to maximize the impact of every report it publishes. PLOS ONE is published by the Public Library of Science (PLOS), the open-access publisher whose goal is to make the world's scientific and medical literature a public resource.

All works published in PLOS ONE are Open Access. Everything is immediately available--to read, download, redistribute, include in databases and otherwise use--without cost to anyone, anywhere, subject only to the condition that the original authors and source are properly attributed. For more information about PLOS ONE relevant to journalists, bloggers and press officers, including details of our press release process and our embargo policy, see the everyONE blog at http://everyone.plos.org/media.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.